Theriva Biologics (TOVX) Enterprise Value (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Enterprise Value of -$14.4 million for Q1 2026, down 44.11% year-over-year from -$25.8 million in Q1 2025, and down 10.53% quarter-over-quarter from -$13.1 million in Q4 2025.
Theriva Biologics (TOVX) Enterprise Value (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Enterprise Value for 17 consecutive years, with -$14.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 44.11% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$14.4 million (down 44.11% YoY), while the FY2025 annual figure was -$13.1 million, down 12.46% from the prior year.
- Enterprise Value declined to -$14.4 million in Q1 2026 per TOVX's latest filing, from -$13.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$7.5 million in Q3 2025 and bottomed at -$56.7 million in Q1 2022.
- Historically, Enterprise Value has averaged -$26.2 million across 5 years, with a median of -$18.3 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value sank 1943.69% — and 2025, when it surged 54.29%.
- Theriva Biologics' Enterprise Value stood at -$41.8 million in 2022, then surged by 44.53% to -$23.2 million in 2023, then surged by 49.91% to -$11.6 million in 2024, then declined by 12.46% to -$13.1 million in 2025, then decreased by 10.53% to -$14.4 million in 2026.
- Business Quant data shows TOVX's Enterprise Value at -$14.4 million in Q1 2026, -$13.1 million in Q4 2025, and -$7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -11.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.34 Mn |
| Mar 31, 2026 | -14.43 Mn |
| Dec 31, 2025 | -13.06 Mn |
| Sep 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -12.10 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Dec 31, 2024 | -11.61 Mn |
| Sep 30, 2024 | -16.41 Mn |
| Jun 30, 2024 | -16.59 Mn |
| Mar 31, 2024 | -18.26 Mn |
| Dec 31, 2023 | -23.18 Mn |
| Sep 30, 2023 | -31.16 Mn |
| Jun 30, 2023 | -34.25 Mn |
| Mar 31, 2023 | -36.08 Mn |
| Dec 31, 2022 | -41.79 Mn |
| Sep 30, 2022 | -50.49 Mn |
| Jun 30, 2022 | -52.27 Mn |
| Mar 31, 2022 | -56.69 Mn |
| Dec 31, 2021 | -67.33 Mn |
| Sep 30, 2021 | -74.91 Mn |